Posted on 15/10/2009 in Pharmaceutical Company Product News Pfizer has revealed that it has come to an agreement with Mylan concerning the antifungal agent Vfend (voriconazole).
The firm will work with two of Mylan's subsidiaries to establish a settlement and license agreement for a generic version of the treatment.
Collaboration between the three organisations will focus on the tablet form of the antifungal agent Vfend only and does not cover Pfizer's Vfend products for intravenous use or oral suspension.
Under the terms of the agreement, Mylan will reserve the rights to market voriconazole tablets during the first quarter of 2011, although other details of the partnership have not yet been disclosed.
It is also subject to the approval of the department of justice and the federal trade commission.
Last week, Pfizer revealed that the Antiviral Drugs Advisory Committee of the Food and Drug Administration voted ten to four to recommend the approval of Selzentry (maraviroc) tablets for use in treatment-naive adult patients with the CCR5-tropic HIV-1 virus, as part of combination therapy.
Other news stories from 15/10/2009
Read more in the Zenopa News Archive
How this news is generated
|
